May is something of a key month for Eylea (aflibercept), one of the largest biosimilar opportunities set to materialize in the current decade. Its US market exclusivity will officially run its course on 17 May, allowing the US Food and Drug Administration to begin approving biosimilars to the multi-billion-dollar treatment for neovascular age-related macular degeneration and diabetic macular edema.
However, rivals are unlikely to reach the market any time soon, as the originator currently has several aflibercept biosimilar sponsors